Magdi Elsallab, MD, PhD

🚨 Exciting News! 🚨
The largest analysis of cell and gene therapy clinical development success probabilities is here!

What we did:
- Analyzed 900+ cell and gene therapies and 2,500 clinical trials to build 1,900 development programs.

Read here
onlinelibrary.wiley.com/share/author/H…

Great overview of the cellular immunotherapy landscape.

Happy to see our work on the cover of @BloodJournal! If you haven’t read it yet, check out our study analyzing FDA adverse event reports for second primary malignancies post-CAR T cells:
authors.elsevier.com/a/1j5wZ1UYwnBkJ

Glad to extend further on the local manufacturing story of immune effector cells (IECs). Out now in @ASTCT_Journal. We surveyed 157 FACT-accredited facilities in the US for their readiness for local manufacturing. The bottom line: a two-stage approach. First, we can leverage academic Good Manufacturing Practice facilities for local manufacturing. Second, we support facilities for minimal manipulation to be ready for local manufacturing. How far are we? I would say not far, but we need to put in the work.

Read here astctjournal.org/article/S2666-…

Hot off the press! Our work on second primary malignancies after commercial CAR T cells is out today in Blood. The FDA released scant information regarding the cases of T cell malignancies after CAR T therapy. Here, we provide more context by diving deep into the FDA Adverse Events Reporting System (FAERS).
Read here 👉🏼doi.org/10.1182/blood.…